InsiderTrades

Form 4 for OVID Ovid Therapeutics Inc.

Accepted 2025-12-18 00:00:00 ET · period of report 2025-12-11 · accession 0001256153-25-000004 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-12-18 2025-12-15 OVID LEVIN JEREMY M CEO, Dir C - Cnv Deriv — +71.0K 3.69M +2% —
D 2025-12-18 2025-12-15 OVID LEVIN JEREMY M CEO, Dir C - Cnv Deriv $0.00 -71 0 -100% $0
DM 2025-12-18 2025-12-11 OVID LEVIN JEREMY M CEO, Dir P - Purchase — +82.9K 35.5K New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-12-15 C A 71,000 — 3,687,715 D — — (F1) Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025.
2 Derivative Series B Convertible Preferred Stock 2025-12-15 C D 71 $0.00 0 D — · — to — 71,000 Common Stock (F1) Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025.
3 Derivative Series A Warrant (right to buy) 2025-12-11 P A 47,333 — 47,333 D $1.40 · — to — 47,333 Common Stock (F3) The reported securities are included within 71 investment units purchased by the Reporting Person for $1,400 per investment unit. Each investment unit consists of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock. (F4) Each Series A Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025. (F5) The Series A Warrants will terminate upon the earlier of (a) the 30th calendar day following date on which we publicly announce the clearance of the first of any investigational new drug application, clinical trial application or other foreign equivalent with respect to the clinical development of our OV4071 product candidate; provided that such 30-calendar day period shall not commence unless and until a registration statement covering the resale of the shares of Common Stock issuable upon exercise of the Series A Warrants is effective; and (b) October 6, 2030.
4 Derivative Series B Convertible Preferred Stock 2025-12-11 P A 71 — 71 D — · — to — 71,000 Common Stock (F3) The reported securities are included within 71 investment units purchased by the Reporting Person for $1,400 per investment unit. Each investment unit consists of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock. (F1) Each share of Series B Convertible Preferred Stock automatically converted into 1,000 shares Common Stock at 5 p.m. Eastern Time on December 15, 2025, pursuant to the approval of the Issuer's Stockholders on December 11, 2025.
5 Derivative Series B Warrant (right to buy) 2025-12-11 P A 35,500 — 35,500 D $1.40 · — to 2030-10-06 35,500 Common Stock (F3) The reported securities are included within 71 investment units purchased by the Reporting Person for $1,400 per investment unit. Each investment unit consists of one share of Series B Convertible Preferred Stock, one Series A Warrant to purchase 666.66 shares of common stock, and one Series B Warrant to purchase 500 shares of common stock. (F6) Each Series B Warrant became immediately exercisable pursuant to the approval of the Issuer's Stockholders on December 11, 2025.